HPV gives rise to a distinct clinical entity of oropharyngeal squamous-cell carcinomas (OPSCC) with a substantially better prognosis than HPV-negative OPSCC, often related to tobacco and alcohol consumption ([@bib7]). Although the incidence of OPSCC has been reported to be increasing in the Western world, including Denmark ([@bib4]), a parallel decline in the incidence of tobacco/alcohol-related head and neck cancers has been observed in most countries, consistent with reduced tobacco use ([@bib12]). Accordingly, we recently demonstrated that the increasing incidence of palatine tonsillar squamous-cell carcinoma (TSCC) in eastern Denmark from 2000 to 2010 may be attributed to an increased number of HPV-positive cases ([@bib4]). The base of the tongue comprising the lingual tonsils has a tissue structure similar to the palatine tonsil, which has been associated with oropharyngeal HPV infection and cancer ([@bib2]). However, few studies focused specifically on the epidemiology of HPV in base of tongue squamous-cell carcinomas (BSCCs), even though BSCC is the second most common OPSCC (after TSCC) in Denmark and other Western countries ([@bib1]).

Previous studies reported highly variable BSCC HPV prevalence ranging from 2% in Northern Spain, 1990--2009 ([@bib10]), to 68% in the USA, 1996--2007 ([@bib11]). According to two reports from Sweden, 40% and 75% of BSCC specimens were HPV-positive, 1970--2002 and 1998--2007, respectively ([@bib3]; [@bib1]). These studies represented relatively small patient series, with the number of cases ranging from 25 to 108 ([@bib3]; [@bib10]). It is unclear whether the wide range in the reported HPV prevalence represents the true impact of HPV on BSCCs or if the deviations are caused by other factors, including variations in study time, geography and/or differences in the sensitivity and specificity of the HPV-detection techniques used ([@bib5]).

On the basis of this inconsistency, we included the largest, non-selected, consecutive cohort comprising all BSCC patients diagnosed in eastern Denmark during an 11-year study period (2000--2010). The aims were to explore whether the incidence of BSCCs increased from 2000 to 2010, whether HPV may explain the increase and to assess the HPV DNA prevalence and its association with gender and age. Furthermore, we examined the HPV genotypes in HPV-positive BSCCs and determined the correlation between HPV DNA PCR and p16 IHC.

Materials and methods
=====================

Patients and tumour samples
---------------------------

We identified all patients registered with base of tongue cancer in eastern Denmark from 2000 to 2010 in the Danish Head and Neck Cancer Group (DAHANCA) Database ([www.dahanca.dk](http://www.dahanca.dk)). We also linked our cohort to the Danish Pathology Data Bank using the personal identification codes as previously described ([@bib4]). The geographical area of eastern Denmark contains ∼45% of the Danish population ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}), and BSCCs represent ∼20% of Danish OPSCCs ([@bib6]). The current study was conducted according to the Helsinki Declaration. It was approved by the Regional Scientific Ethical Committee (H-C-2008-080) and the Danish Data Protection Agency.

Review of pathology and laboratory analysis
-------------------------------------------

Specialized head and neck pathologists reviewed all histological tumour specimens and assessed p16 expression by IHC as described earlier ([@bib4]). The handling of the tumour specimens, the DNA isolation and HPV DNA PCR analysis (GP5+/GP6+ primers) were performed as previously reported ([@bib4]).

We performed amplicon-based next-generation sequencing on all HPV DNA-positive samples. We prepared 50 ng of DNA of each sample, and made four pools of 23 samples (pool 1--4) and one pool of 16 samples (pool 5). Each pool was ligated with a unique adaptor using the SPRIworks Fragment Library System (Beckman Coulter, Brea, CA, USA) and subsequently sequenced on the MiSeq (Illumina, San Diego, CA, USA) according to the manufacturer\'s protocol. We normalized pool 5, which only contained 16 samples, to 23 samples using an index of 23/16, and merged the reads from the five pools. The reads were imported into the CLC Main Workbench software (Qiagen, Hilden, Germany) for read mapping against HPV.

Statistical analysis
--------------------

The statistical analyses were done as earlier described ([@bib4]). Because of the limited study period, we used absolute numbers to analyse incidence.

Results
=======

Patient population
------------------

A total of 263 patients with base of tongue cancer were identified in eastern Denmark during 2000--2010 as registered in the DAHANCA database, and 252 patients (96%) were also listed in the Danish Pathology Data Bank ([Figure 1](#fig1){ref-type="fig"}). We were able to retrieve the tumour specimens on 239 patients and 221 of these were recognised as squamous-cell carcinomas. Our final data set comprised 210 patients with specimens suitable for HPV detection. Patients included in the study were similar in terms of age, gender and year of diagnosis compared with those excluded ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Overall, HPV DNA was present in 51% (108/210) of BSCCs.

Trends in BSCC incidence in eastern Denmark, 2000--2010
-------------------------------------------------------

The total number of BSCC patients increased significantly from 2000 to 2010 (annual percentage change (APC), 5.4% 95% CI, 1.0--10.1% [Figure 2](#fig2){ref-type="fig"}). The number of HPV-positive patients also increased significantly during the study period (APC, 8.1% 95% CI, 1.7--14.9%). In contrast, the number of HPV-negative patients did not change significantly (APC, 2.7% 95% CI, −3.4--9.2%).

HPV genotyping
--------------

We mapped a total of 7 894 496 reads against HPV of which 7 576 378 (96%) reads were equivalent to HPV16, 185 028 (2.3%) reads represented HPV35, 72 873 reads (0.9%) corresponded to HPV45 and 60 217 reads (0.8%) were identified as HPV33.

Factors associated with HPV-positivity
--------------------------------------

We found no significant association of HPV prevalence with age, although patients \<60 years had a higher HPV prevalence (55%) than patients ⩾60 years (48% odds ratio (OR) ⩾60 *vs* \<60, 1.46; 95% CI, 0.78--2.36; *P*=0.27). Likewise, the HPV prevalence among female and male patients was similar (45% and 55%, respectively; OR female *vs* male, 0.68; 95% CI, 0.38--1.24; *P*=0.21).

In total, 52% (110/210) of the specimens were p16 positive. HPV DNA PCR and p16 IHC, were in agreement in 88% of BSCCs ([Table 1](#tbl1){ref-type="table"}) (Kappa=0.75; 95% CI, 0.67--0.85). The discordant outcomes, HPV^+^/p16^−^ and HPV^−^/p16^+^, were observed in 5.5% and 6.5% of BSCCs, respectively.

Discussion
==========

In the present study, we included 210 DAHANCA BSCC patients representing eastern Denmark from 2000 to 2010. It is the largest, non-selected, consecutive cohort of BSCCs to date, and it covers an area of ∼45% of the Danish population. We identified an overall HPV DNA prevalence of 51%, and observed an increase in the number of HPV DNA-positive BSCCs, which may explain the increasing incidence of total BSCCs during the study period. To the best of our knowledge, this has not been reported previously.

The identified HPV DNA prevalence is lower than those reported in studies on BSCCs from Sweden and the USA ([@bib1]; [@bib11]), and slightly lower than that observed in our TSCC study ([@bib4]). Still, because of the size of our study, the results are likely to be a more general representation of BSCC patients in Denmark.

We observed a trend towards an association of HPV prevalence with younger age; however, the association did not reach statistical significance. This may be related to the number of included patients. Nevertheless, our results add to the discussion on the relevance of male HPV vaccination in Denmark, given that HPV16 was the predominant HPV type in both BSCCs and TSCCs ([@bib4]).

One of the advantages of our study is that we examined both the HPV DNA and the p16 status using validated HPV DNA PCR primers ([@bib7]) and a high cutoff for p16 expression by IHC. The majority (96/108, 89%) of HPV DNA-positive BSCCs were also p16 positive, implying an HPV-associated carcinogenesis. In contrast, some reports on the improved survival of HPV-positive OPSCCs have only used p16 as surrogate marker for HPV ([@bib8]), even though p16 overexpression is not specific to HPV ([@bib9]).

The current treatment regimen for OPSCC typically involves chemoradiotherapy without inclusion of HPV status. It is an intense therapy associated with considerable morbidity. A subgroup of HPV-positive BSCCs (and TSCCs) may not need such treatment why several clinical trials are investigating strategies for treatment de-escalating. Furthermore, transoral robotic surgery may also represent a new, gentler treatment option. This highlights the importance of how to define HPV-positivity, and emphasizes the need for studies that focus on the effect of both HPV and p16 for the prognosis.

In conclusion, we found that the observed increase in the number of HPV-positive BSCCs may explain the increasing incidence of BSCC in eastern Denmark, 2000--2010. We found HPV DNA in 51% of BSCCs with HPV16 as the predominant HPV type and a good correlation between HPV DNA PCR and p16 IHC. Therefore, we suggest to measure both parameters and to include both TSCCs and BSCCs when estimating the number of HPV-positive OPSCCs.
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![**Overview of exclusions and final study population.** Excluded patients are indicated as number of patients (*n*) and percentage of total.](bjc2015198f1){#fig1}

![**Number of total BSCCs according to HPV status.** The black circles represent the total number of BSCCs per year; the black line is an estimated regression line showing a significant increase in the number of patients with BSCC (5.4% per year). The red squares represent the number of patients with HPV-positive BSCCs per year; the red line is an estimated regression line showing a significant increase in the number of patients with HPV-positive BSCCs (8.1% per year). The green triangles represent the number of patients with HPV-negative BSCCs per year; the green line is an estimated regression line showing no significant increase in the number of patients with HPV-negative BSCCs (2.7% per year). Abbreviations: APC=annual percentage change; CI=confidence interval.](bjc2015198f2){#fig2}

###### Distribution of patients according to HPV DNA PCR and p16 IHC

  **BSCCs**      **HPV-negative**   **HPV-positive**
  -------------- ------------------ ------------------
  p16 negative   88 (42%)           12 (5.5%)
  p16 positive   14 (6.5%)          96 (46%)

Abbreviation: CI, confidence interval.

The 2 × 2 table shows the number of patients with the corresponding HPV and p16 profile and the percentage of total, as well as the kappa value, including the 95% CI.
